期刊文献+

马来酸替加色罗分散片的人体生物等效性研究 被引量:1

Assessment on Bioequivalence of Tegaserod Maleate Dispersible Tablets in Human Body
原文传递
导出
摘要 目的:研究马来酸替加色罗分散片的人体生物等效性。方法:22名健康男性志愿者随机交叉单剂量口服马来酸替加色罗分散片(受试制荆)和马来酸替加色罗片(参比制剂)6mg,采用LC/MS/MS法测定人血浆中药物浓度。结果:受试制剂和参比制剂的tmax分别为(0.86±0.22)、(1.01±0.24)h Cmax分别为(2.21±0.69)、(2.05±0.64)ng·mL^-1,AUC0~17分别为(6.35±2.48)和(6.47±1.99)ng·h·mL^-1,AUC0-∞分别为(6.69±2.59)、(6.70±2.03)ng·h·mL^-1。受试制剂相对于参比制剂的生物利用度为(98.2±22.1)%。结论:两种制剂具有生物等效性。 OBJECTIVE: To study the bioequivalence of tegaserod maleate dispersible tablets in healthy volunteers. METHODS:A single oral dose of 6mg test or reference preparations of tegaserod maleate was given to 22 healthy volunteers in a randomized crossover study.The plasma concentrations of tegaserod were determined by LC/MS/MS assay.RESULTS:The main pharmacokinetic parameters of test and reference products were as follows: tmax(0.86±0.22) and(1.01 ± 0.24) h; Cmax (2.21 ±0.69) and (2.05±0.64) ng·mL^-1AUC0-17(6.35±2.48) and(6.47±1.99)ng·h·mL^-1 AUC0-∞(6.69±2.59) and (6.70± 2.03)ng ·h · mL^ -1,respectively.The relative bioavailability of test to reference preparation was(98.2± 22.1) % .CONCLUSION:The reference preparation and the test preparation are bioequivalent.
出处 《中国药房》 CAS CSCD 北大核心 2007年第8期592-594,共3页 China Pharmacy
关键词 马来酸替加色罗分散片 LC/MS/MS法 生物等效性 Tegaserod maleate dispersible tablet LC/MS/MS Bioequivalence
  • 相关文献

参考文献6

二级参考文献36

  • 1王孟琴,田淑媛.钾镁分散片的研制及临床观察[J].西北药学杂志,1994,9(4):175-176. 被引量:2
  • 2罗云,马红斌,蔡鸿生.扑热息痛分散片制备及质量控制[J].现代应用药学,1996,13(3):34-35. 被引量:4
  • 3王卓,韩丽梅,张晓青,邓英杰,张艳华,王越.利用均匀设计筛选阿司匹林分散片处方[J].沈阳药科大学学报,1996,13(4):235-239. 被引量:18
  • 4JAIN A, TOUGAS G. Tegaserod-a novel therapeutic agent for irritable bowel syndrome[J ]. Today' s Ther Trends, 2001, 19 (2) : 105-116.
  • 5CAMILLER.I M. Review article: tegaserod[J]. Aliment Pharmacol Ther, 2001, 15(3): 277-289.
  • 6APPEL S, KUMLE A, HUBERT M, et al. First pharmacokinetic-pharmacodynamic study in humans with a selective 5-hydroxytryptamine4 receptor agonist [ J ]. J Clin Pharmacol, 1997, 37 (3) :229-237.
  • 7Lethaby A,Augood C,Duckitt K. Nonsteroidal anti-inflammatory drugs for heavy menstrual bleeding[J]. Cochrane Database Syst Rev,2002, (1): CD000400.
  • 8AL-Waili NS. Treatment of menstrual migraine with prostaglandin synthesis inhibitor mefenamic acid: double-blind study with placebo[J]. Eur J Med Res,2000,19, 5(4):176~182.
  • 9Rouini MR, Asadipour A, Ardakani YH, et al. Liquid chromatography method for determination of mefenamic acid in human serum[J]. Journal of Chromatography B, 2004,800 (1~2): 189~192.
  • 10Ruiz TP, Lozano CM, Tomás V, et al. Analysis of binary mixtures of flufenamic, meclofenamic and mefenamic acids by derivative synchronous fluorescence spectrometry[J]. Talanta, 1998,47(3):537~545.

共引文献49

同被引文献6

  • 1司继刚,郭瑞臣,王本杰.马来酸替加色罗胶囊与其片剂的人体生物等效性[J].中国临床药学杂志,2006,15(2):96-99. 被引量:6
  • 2司继刚,王本杰,郭瑞臣.马来酸替加色罗片健康人体药代动力学试验[J].齐鲁药事,2006,25(6):365-367. 被引量:1
  • 3Viekers AE, Zollinger M, Dannecker R. et al. In vitro metabolism of tegaserod in human liver and intestine: assessment of drug interactions[J]. Drug Metab Disp, 2001 ;29:1269 - 1276.
  • 4Appel S, Kumle A, Hubert M, et al. First pharmacokineticpharmacodynamic study in humans with a selective 5-hydroxytryptamine 4 receptor agonist [ J]. J Clin Pharmacol, 1997;37:229 - 237.
  • 5Appel-Dingemanse S. Clinical pharmacokinetics of tegaserod, a serotonin 5-HT(4) receptor partial agonist with promotile activity [J]. Clin Pharmacokinet, 21302;41 : 1021 - 1042.
  • 6张乐之,魏斌,周红.马来酸替加色罗[J].中国新药杂志,2002,11(12):968-969. 被引量:3

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部